Company / Net Income
Theravance Biopharma, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$105.9M
FY2025
5-year range
-$278.0M / $105.9M
FY2021-FY2025
Trend
+287.7%
vs FY2024
Sector context
#42 of 216
Health Care
What the data says
Net Income changed +288% YoY in FY2025, a notable deviation from the 9-year average annual change of +32%.
Based on SEC 10-K filings.
$106M in FY2025. Top quartile in the Health Care sector.
Improved from -$55M to $106M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 216This company $105.9M Sector average $454.3M
▼
-76.7% below sector average
Key checks
Key Insights
- In FY2025, net income increased 287.7% year-over-year.
- Ranks #42 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $105.9M | +287.7% |
| FY2024 | -$56.4M | -2.2% |
| FY2023 | -$55.2M | +80.1% |
| FY2022 | -$278.0M | -39.4% |
| FY2021 | -$199.4M | +28.3% |
| FY2020 | -$278.0M | +2.6% |
| FY2019 | -$285.4M | -49.7% |
| FY2018 | -$190.7M | +33.2% |
| FY2017 | -$285.4M | -49.7% |
| FY2016 | -$190.7M | -22.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026